309: Psychedelics at the FDA, ASCO recap, & MorphoSys update
The Readout Loud
00:00
Novartis's Acquisition of Morphosis and FDA Approval Challenges
The chapter delves into Novartis's acquisition of Morphosis and the challenges faced with FDA approval for the drug Pelabresib for myelofibrosis. It also discusses a pharmaceutical company's ambiguity in announcing FDA approval intentions for a new drug, leading to uncertainty and concerns.
Transcript
Play full episode
